Browse drugs

…reatment resulted in 70-95% tumor growth inhibition.Conclusions IMM-2510 is an anti-PD-L1xVEGF bispecific antibody designed to have immu…

…ce Moon S, Zhao F, Uddin MN, Tucker CJ, Karmaus PW, Fessler MB. Flotillin-2 dampens T cell antigen sensitivity and functionality. JCI Insig…

…in only marginal tumor control (<40% TGI) without achieving CR. HM16390 elicited an improved, yet still insufficient, anti-tumor activi…

…nostimulatory activity, and therapeutic utility. Conjugation of cs21 to CD45 targeting antibodies permits safe and efficacious intra…

…on of cells halted in G2 (DAPI-high, Edu-low) when treated with PARPi. When compared across cell divisions, the effect was most prono…

…uppression of TRAMP-C2 and RM-1 tumors compared to mSTAR1302 or Olaparib monotherapies. In both models, combination therapy resulted in …

…D8 T cells compared to FMP alone. However, co-administration of SAP-3 or α-GalCer increased the proportion of poly-functional CD8 T c…

…inical application has been challenged by significant toxicity. CT-P72/ABP-102 is a tetravalent bispecific HER2 and CD3 T-cell engager enginee…

…ducted on 38 patients with 41 lung lesions (n=41) who underwent Tektrotyd SPECT between March 2012 and April 2023 for suspected lung NENs…

…otrexate and Sulfasalazine as well as biological agents such as Adalimumab and Rituximab. Here, we therefore compare real-world experience…

… Chi 2=6.6, p=0.0092).In Cox proportional hazard modelling, low testosterone increased risk of death (HR=2.23, p=0.038) when accounting for …

…omography), and histological/MPM strut coverage were evaluated. Rosuvastatin serum concentration was correlated with endothelial cell covera…